Announcements Trials
Browse Landscape

Phase

Phase 2 30Phase 3 23Phase 1/2 13Phase 1 8Phase 2/3 4Phase EARLY_PHASE1 2Phase NA 1Phase 4 1

Status

Active not recruiting 2

Sponsor Class

OTHER 1NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2

Conditions

Lymphoma, Mantle-Cell 1Lymphoma, B-Cell 1Lymphoma 1

Interventions

pembrolizumab 4Nivolumab 4Magnetic Resonance Spectroscopy 4Temozolomide 2Specimen Handling 2Rituximab 2Radiotherapy 2Radiosurgery 2Paclitaxel 2Neoadjuvant Therapy 2Gemcitabine 2Dexamethasone 2Cisplatin 2Carboplatin 2venetoclax 1theanine 1temsirolimus 1tafasitamab 1sugemalimab 1senicapoc 1sacituzumab govitecan 1ruxolitinib 1perampanel 1paricalcitol 1pamiparib 1olaparib 1lutetium Lu 177 dotatate 1irinotecan sucrosofate 1glofitamab 1gadobutrol 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Rituximab × 30 days × Clear all
NCT05495464 2026-05-20

A Pilot "Window-3" Study of Acalabrutinib Plus Rituximab Followed by Brexucabtagene Autoleucel Therapy in Patients With Previously Untreated High-risk Mantle Cell Lymphoma

M.D. Anderson Cancer Center

Phase EARLY_PHASE1 Active not recruiting
22 enrolled
Lymphoid

Lymphoma, Lymphoma, Mantle-Cell

NCT04161248 2026-05-12

Phase I Master Protocol of Novel Combination Therapy for Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma

Canadian Cancer Trials Group

Phase EARLY_PHASE1 Active not recruiting
40 enrolled
Lymphoid

Lymphoma, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡